Equine Herpesvirus vaccination protects horses from respiratory disease, abortion, and neurological complications. Understanding schedules, coverage, and regional risks helps owners and veterinarians build practical prevention plans.
Modern vaccines combine traditional inactivated components with newer modified-live technologies, improving immune response while managing reactogenicity. Below is a structured reference to support clinical decisions and informed discussions with your veterinarian.
| Vaccine Type | Common Targets | Route | Typical Initial Series |
|---|---|---|---|
| Inactivated (killed) | EHV-1, EHV-4 | Intramuscular | 2–3 doses, 4–6 weeks apart |
| Modified-live | EHV-1, EHV-4 | Intranasal or intramuscular | 1–2 doses, 4–6 weeks apart |
| Multivalent | EHV plus influenza, rhinopneumonitis, tetanus | Intramuscular | Aligned with risk-based protocols |
| Pregnant mare specific | EHV-1 abortion prevention | Intramuscular | Monthly from month 5–9 of gestation |
Vaccine Types And Mechanism Of Action
Different platforms influence how the immune system recognizes EHV. Inactivated vaccines present killed virus, prompting a controlled immune response with low risk of reversion. Modified-live vaccines introduce a weakened form of the virus, often generating stronger and longer-lasting immunity but requiring careful handling and administration by a veterinarian.
Scheduling And Primary Immunization
Foals And Young Horses
Healthy foals may receive initial vaccination as early as three months, with boosters every four to six weeks to complete the series. This schedule compensates for waning maternal antibodies and helps establish solid immunological memory before higher exposure risk periods.
Adult Competitive And Leisure Horses
Performance animals often follow a more intense schedule, especially before travel or shows. A two-dose initial series spaced by four to six weeks, followed by semiannual boosters, is common for many EHV types depending on regional risk and event demands.
Pregnant Mare Strategies
Vaccinating pregnant mares protects both the mare and the unborn foal by reducing the risk of EHV-1 abortion. Modified-live and specific inactivated products are used strategically, usually starting around the fifth month of gestation and repeated at monthly intervals through the remainder of pregnancy.
Regional Risk And Outbreak Management
Areas with previous neurologic EHV-1 outbreaks may benefit from more rigorous protocols, including additional boosters and strict biosecurity. Monitoring local veterinary reports and adjusting timing before peak transmission seasons can reduce the likelihood of explosive herd-level issues.
Key Recommendations
- Follow a risk-based schedule tailored to age, use, and local outbreak history.
- Pregnant mares should receive regular boosters per veterinary guidance, typically from months five to nine of gestation.
- Plan vaccination at least two weeks before anticipated stress events such as travel or competition.
- Monitor for mild reactions and contact your veterinarian if you observe persistent fever, swelling, or neurological signs.
- Combine vaccination with robust biosecurity, including isolation of new arrivals and hygiene protocols in stables.
FAQ
Reader questions
How soon after vaccination can I travel my horse to a show?
Many veterinarians recommend waiting two weeks after the final dose in the initial series or after a booster to allow optimal immune protection. Confirm show-specific entry rules, as some require proof of vaccination within a specific window before arrival.
What are the most common side effects of EHV vaccination?
Most horses experience mild soreness at the injection site, transient fever, or slight lethargy for 24–48 hours. Severe allergic reactions are rare but require immediate veterinary attention if facial swelling, hives, or breathing difficulties occur.
Can vaccination completely prevent EHV abortion in mares?
Vaccination significantly lowers the risk of abortion caused by EHV-1, but it does not eliminate it entirely. Combining vaccination with strict biosecurity for pregnant mares and prompt veterinary care at signs of pregnancy loss offers the best protection.
Is an intranasal EHV vaccine as effective as an intramuscular one?
Intranasal vaccines often generate stronger local mucosal immunity against respiratory shedding, while intramuscular products provide reliable systemic protection. Choosing between them depends on age, pregnancy status, risk of respiratory versus reproductive disease, and your veterinarian’s recommendation.